Phase I and II clinical trials of fresolimumab (a monoclonal anti-TGFβ antibody) have been conducted in renal cell carcinoma, melanoma, mesothelioma, and breast cancer [43,44,45]. This evidence concerns the gene TGFB1 and hereditary clear cell renal cell carcinoma.